Loading...

Catriona Jamieson

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0695
La Jolla CA 92093
Phone858-534-7128
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Jamieson specialized in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies. In the past two years, Dr. Jamieson’s stem-cell research studies have taken a great leap: from identifying a promising treatment in the laboratory to opening and completing the first clinical trial to target cancer stem cells in humans. This trial is the result of teamwork that has brought together her discoveries in myeloproliferative neoplasms and a local pharmaceutical company’s drug development track.

    Education and Training
    BS - Biology-Genetics, University of British Columbia - 1987
    Ph.D. - Microbiology, University of British Columbia - 1992
    MD - University of British Columbia - 1995
    Resident - University of British Columbia - 1995-1998
    Fellow, Bone Marrow Transplant - University of British Columbia - 1998
    Fellow, Bone Marrow Transplant - Stanford University - 1999-2002
    Postdoctoral Research Fellow - Stanford University - 2002-2005


    Collapse Research 
    Collapse Research Activities and Funding
    Defining the Niche-dependent Role of RNA Editing in Aged and MDS Hematopoietic Stem and Progenitor Cell Dysfunction
    NIH/NIDDK R01DK114468Aug 20, 2017 - Jul 31, 2022
    Role: Principal Investigator
    Characterization of the Role of ADAR1 in Oncogenic Transformation of Progenitors
    NIH/NCI R01CA205944Dec 8, 2016 - Nov 30, 2021
    Role: Principal Investigator
    (PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance
    NIH/NCI R21CA194679May 1, 2015 - Apr 30, 2017
    Role: Principal Investigator
    Identifying microRNA Targets for Early Detection of Myeloproliferative Neoplasms
    NIH/NCI R21CA189705Apr 1, 2015 - Mar 31, 2017
    Role: Principal Investigator
    2009 Stem Cells and Cancer Gordon Conference
    NIH/NCI R13CA139606Sep 1, 2009 - Aug 31, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. PMID: 29859176.
      View in: PubMed
    2. Curtis E, Martin JR, Gabel B, Sidhu N, Rzesiewicz TK, Mandeville R, Van Gorp S, Leerink M, Tadokoro T, Marsala S, Jamieson C, Marsala M, Ciacci JD. A First-in-Human, Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury. Cell Stem Cell. 2018 Jun 01; 22(6):941-950.e6. PMID: 29859175.
      View in: PubMed
    3. Jamieson C, Millan MT, Creasey AA, Lomax G, Donohoe ME, Walters MC, Abedi M, Bota DA, Zaia JA, Adams JS. CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell Stem Cell. 2018 Jun 01; 22(6):801-805. PMID: 29859170.
      View in: PubMed
    4. Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G. The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards? Stem Cell Reports. 2018 May 08; 10(5):1429-1431. PMID: 29742388.
      View in: PubMed
    5. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018 Mar 08. PMID: 29522138.
      View in: PubMed
    6. Jiang Q, Jamieson C. BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms. Cancer Cell. 2018 Jan 08; 33(1):3-5. PMID: 29316431.
      View in: PubMed
    7. Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson C. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun. 2017 Dec 04; 8(1):1922. PMID: 29203771.
      View in: PubMed
    8. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017 Oct; 15(10):1193-1207. PMID: 28982745.
      View in: PubMed
    9. Jamieson C. Cancer: Bad blood promotes tumour progression. Nature. 2017 09 27; 549(7673):465-466. PMID: 28959960.
      View in: PubMed
    10. Jiang Q, Crews LA, Holm F, Jamieson C. RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer. 2017 06; 17(6):381-392. PMID: 28416802.
      View in: PubMed
    11. Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 12; 14(12):1572-1611. PMID: 27956542.
      View in: PubMed
    12. Ha D, Liao X, Wang HY, Jamieson C, Magaña M, Makani S. Thoracic Extramedullary Hematopoiesis Mimicking Metastatic Cancer. J Bronchology Interv Pulmonol. 2016 Oct; 23(4):343-346. PMID: 27479013.
      View in: PubMed
    13. Hirata T, Park SC, Muldong MT, Wu CN, Yamaguchi T, Strasner A, Raheem O, Kumon H, Sah RL, Cacalano NA, Jamieson CHM, Kane CJ, Masuda K, Kulidjian AA, Jamieson C. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian J Urol. 2016 Oct; 3(4):229-239. PMID: 29264191.
      View in: PubMed
    14. Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, Lazzari E, Crews LA, Jamieson C, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget. 2016 Aug 30; 7(35):56013-56029. PMID: 27463014.
      View in: PubMed
    15. Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson C. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 11 03; 19(5):599-612. PMID: 27570067.
      View in: PubMed
    16. Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellecchia M, Minden M, Frazer KA, Marra MA, Crews LA, Jiang Q, Jamieson C. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. 2016 08 04; 19(2):177-191. PMID: 27292188.
      View in: PubMed
    17. Pineda G, Lennon KM, Delos Santos NP, Lambert-Fliszar F, Riso GL, Lazzari E, Marra MA, Morris S, Sakaue-Sawano A, Miyawaki A, Jamieson C. Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche. Sci Rep. 2016 Apr 04; 6:23885. PMID: 27041210; PMCID: PMC4819192.
    18. Holm F, Hellqvist E, Mason CN, Ali SA, Delos-Santos N, Barrett CL, Chun HJ, Minden MD, Moore RA, Marra MA, Runza V, Frazer KA, Sadarangani A, Jamieson C. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal. Proc Natl Acad Sci U S A. 2015 Dec 15; 112(50):15444-9. PMID: 26621726; PMCID: PMC4687548.
    19. Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294. PMID: 26357842; PMCID: PMC4566296.
    20. Zipeto MA, Jiang Q, Melese E, Jamieson C. RNA rewriting, recoding, and rewiring in human disease. Trends Mol Med. 2015 Sep; 21(9):549-59. PMID: 26259769.
      View in: PubMed
    21. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015 Aug; 2(8):e339-46. PMID: 26688487.
      View in: PubMed
    22. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. PMID: 26297272; PMCID: PMC4548279.
    23. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr; 13(4):424-34. PMID: 25870379.
      View in: PubMed
    24. Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, Court AC, Goff DJ, Prashad SL, Geron I, Wall R, McPherson JD, Moore RA, Pu M, Bao L, Jackson-Fisher A, Munchhof M, VanArsdale T, Reya T, Morris SR, Minden MD, Messer K, Mikkola HK, Marra MA, Hudson TJ, Jamieson C. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015 Mar 21; 13:98. PMID: 25889765; PMCID: PMC4414375.
    25. DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson C, Carson D, Kipps TJ, Frazer KA. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar; 11(3):e1004105. PMID: 25768983; PMCID: PMC4358997.
    26. Crews LA, Jiang Q, Zipeto MA, Lazzari E, Court AC, Ali S, Barrett CL, Frazer KA, Jamieson C. An RNA editing fingerprint of cancer stem cell reprogramming. J Transl Med. 2015 Feb 12; 13:52. PMID: 25889244; PMCID: PMC4341880.
    27. Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2015 Jul; 56(7):1938-48. PMID: 25330439.
      View in: PubMed
    28. Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D'Antonio M, Ghia EM, Carson DA, Jamieson C, Kipps TJ, Frazer KA. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 07; 15(8):420. PMID: 25103687; PMCID: PMC4165357.
    29. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson C, von Boehmer H, Young RA, Look AT. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 2013 Jul 29; 210(8):1545-57. PMID: 23857984; PMCID: PMC3727321.
    30. Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson C, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One. 2013; 8(3):e58714. PMID: 23527012; PMCID: PMC3604164.
    31. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson C, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013 May; 3(5):564-77. PMID: 23471820; PMCID: PMC3651770.
    32. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson C. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 07; 12(3):316-28. PMID: 23333150; PMCID: PMC3968867.
    33. Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, Frazer KA, Jamieson C. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2013 Jan 15; 110(3):1041-6. PMID: 23275297; PMCID: PMC3549099.
    34. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma. 2013 Jun; 54(6):1151-8. PMID: 23121619; PMCID: PMC3612371.
    35. Newton IG, Plaisted WC, Messina-Graham S, Abrahamsson Schairer AE, Shih AY, Snyder EY, Jamieson C, Mattrey RF. Optical imaging of progenitor cell homing to patient-derived tumors. Contrast Media Mol Imaging. 2012 Nov-Dec; 7(6):525-36. PMID: 22991319; PMCID: PMC4091721.
    36. Crews LA, Jamieson C. Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett. 2013 Sep 10; 338(1):15-22. PMID: 22906415.
      View in: PubMed
    37. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson C, Staudt LM, Young RA, Look AT. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012 Aug 14; 22(2):209-21. PMID: 22897851; PMCID: PMC3422504.
    38. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson C. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012; 7(6):e39725. PMID: 22768113; PMCID: PMC3387267.
    39. Crews LA, Jamieson C. Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep. 2012 Jun; 7(2):125-32. PMID: 22467334; PMCID: PMC3342507.
    40. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson C. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28; 9:185. PMID: 22035283; PMCID: PMC3269442.
    41. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96. PMID: 21220608; PMCID: PMC4979099.
    42. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010 Jul; 120(7):2254-64. PMID: 20592475; PMCID: PMC2898591.
    43. Rice KN, Jamieson C. Molecular pathways to CML stem cells. Int J Hematol. 2010 Jun; 91(5):748-52. PMID: 20533007.
      View in: PubMed
    44. O'Brien CA, Kreso A, Jamieson C. Cancer stem cells and self-renewal. Clin Cancer Res. 2010 Jun 15; 16(12):3113-20. PMID: 20530701.
      View in: PubMed
    45. Jamieson C. Split ends in CML: divergent roles of Hes1. Blood. 2010 Apr 08; 115(14):2726-7. PMID: 20378758.
      View in: PubMed
    46. Goff D, Jamieson C. Cycling toward elimination of leukemic stem cells. Cell Stem Cell. 2010 Apr 02; 6(4):296-7. PMID: 20362532.
      View in: PubMed
    47. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. PMID: 20124220; PMCID: PMC2854430.
    48. Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson C. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010 Feb; 20(2):111-21. PMID: 20080405; PMCID: PMC2856642.
    49. Jaiswal S, Jamieson C, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009 Jul 23; 138(2):271-85. PMID: 19632178; PMCID: PMC2775564.
    50. Zhao C, Chen A, Jamieson C, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009 Apr 09; 458(7239):776-9. PMID: 19169242; PMCID: PMC2946231.
    51. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson C. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A. 2009 Mar 10; 106(10):3925-9. PMID: 19237556; PMCID: PMC2646624.
    52. Jamieson C. The MLLgnant consequences of reverting to an embryonic transcriptional program. Cell Stem Cell. 2009 Feb 06; 4(2):97-8. PMID: 19200795.
      View in: PubMed
    53. Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson C, Wang JYJ, Naoe T. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol. 2008 Dec; 88(5):471-475. PMID: 19039626; PMCID: PMC2626150.
    54. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC, Young DJ, Naoe T, Murre C, Jamieson C, Wang JY. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A. 2008 Nov 18; 105(46):17967-72. PMID: 19004799.
      View in: PubMed
    55. Jamieson C, Barroga CF, Vainchenker WP. Miscreant myeloproliferative disorder stem cells. Leukemia. 2008 Nov; 22(11):2011-9. PMID: 18923436.
      View in: PubMed
    56. Kavalerchik E, Goff D, Jamieson C. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008 Jun 10; 26(17):2911-5. PMID: 18539972.
      View in: PubMed
    57. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson C. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr; 13(4):321-30. PMID: 18394555.
      View in: PubMed
    58. Rossi DJ, Jamieson C, Weissman IL. Stems cells and the pathways to aging and cancer. Cell. 2008 Feb 22; 132(4):681-96. PMID: 18295583.
      View in: PubMed
    59. Jamieson C. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008; 436-42. PMID: 19074122.
      View in: PubMed
    60. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson C, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006 Oct 01; 66(19):9339-44. PMID: 16990346.
      View in: PubMed
    61. Jamieson C, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6224-9. PMID: 16603627; PMCID: PMC1434515.
    62. Jamieson C, Weissman IL, Passegué E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell. 2004 Dec; 6(6):531-3. PMID: 15607956.
      View in: PubMed
    63. Jamieson C, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004 Aug 12; 351(7):657-67. PMID: 15306667.
      View in: PubMed
    64. Jamieson C, Amylon MD, Wong RM, Blume KG. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol. 2003 Oct; 31(10):981-6. PMID: 14550815.
      View in: PubMed
    65. Passegué E, Jamieson C, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003 Sep 30; 100 Suppl 1:11842-9. PMID: 14504387; PMCID: PMC304096.